Opendata, web and dolomites

TRANSBIO

Cellular BIOtechnology for prognosis and monitoring in renal TRANSplantation

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "TRANSBIO" data sheet

The following table provides information about the project.

Coordinator
BIOHOPE SCIENTIFIC SOLUTIONS FOR HUMAN HEALTH SL 

Organization address
address: CALLE SANTIAGO GRISOLIA 2 PARQUE TECNOLOGICO DE MADRID
city: TRES CANTOS MADRID
postcode: 28760
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website https://transbiohope.eu/
 Total cost 3˙846˙640 €
 EC max contribution 3˙845˙140 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2017
 Duration (year-month-day) from 2017-01-01   to  2019-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BIOHOPE SCIENTIFIC SOLUTIONS FOR HUMAN HEALTH SL ES (TRES CANTOS MADRID) coordinator 3˙845˙140.00

Map

 Project objective

Kidney transplantation is the treatment of choice for patients with end-stage kidney disease (ESKD). However, although surgical techniques and postoperative care have greatly advanced, renal transplantation is not empty of challenges. The most important challenge is to achieve the long-term survival of the transplanted organ. Graft survival depends on the ability of the recipe of not rejecting the “foreign organ”. Rejection is a naturally occurring process triggered by a biological response of the immune system, which main function in the body is to defend it against infectious organisms and other invaders. As such, the immune system is prepared to reject a “foreign organ”, something that is nowadays prevented by prescribing immunosuppressive therapies to the patients for their whole life. However, the use of immunosuppressive therapies entails important problems. On one side, suppressing the immune system implies severe side effects like opportunistic infections, cancer and other severe malignancies. On the other side, even under immunosuppressive therapies, about 50% of transplanted kidneys are lost during the first 10 years and this is because of an immune response usually described as chronic rejection. Therefore, the major challenges in ESKD deal with avoiding the side effects associated with immunosuppressant drugs and avoiding chronic rejection. In the TRANSBIO project we aim at bringing to the healthcare market a technology for efficient clinical management of patients undergoing a kidney transplant based on a simple and non-invasive blood test. Considering that worldwide, the number of people receiving renal transplantation annually is estimated at about 80,000 people, growing by approximately 6% annually and representing a prevalence of about 700 patients per million population, or what is the same about 5 million people living with a transplanted kidney, the TRANSBIO business opportunity seems unquestionable.

 Deliverables

List of deliverables.
TRANSBIO webpage Websites, patent fillings, videos etc. 2020-02-27 11:28:30

Take a look to the deliverables list in detail:  detailed list of TRANSBIO deliverables.

 Publications

year authors and title journal last update
List of publications.
2018 M. Di Scala1, J. Portolés2, C. Jiménez3, D. Janeiro2, E. González3, B. Sánchez Sobrino2, M. López Oliva3, J. Richter1, A. Ortega1, J. Pascual4, I. Portero1; 1 BIOHOPE Scientific SL, Madrid, Spain 2 Hospital Universitario Puerta de Hierro, Nephrology Department, Madrid, Spain, 3 Hospital La Paz, Nephrology Department, Madrid, Spain, 4 Hospital del Mar, Nephrology Department and Kidney Transplantation, Barcelona, Spain.
IMMUNOBIOGRAM a new immunological tool to personalize immunosuppressive therapy in kidney transplant recipients
published pages: https://www.eci2, ISSN: , DOI:
Abstracts Book, 5th European Congress of Immunology, 2-5 September Amsterdam Annual 2020-02-27
2018 Ortega-Carrión Álvaro1, Di Scala Marianna1, Yebra Tatiana1, Diez Teresa 1, Richter Jose1, Portero Isabel1 1 BIOHOPE Scientific SL, Tres Cantos, Madrid, Spain
Immunobiogram: Patterns of resistance to immunomodulatory treatment in patients with chronic inflammatory diseases
published pages: https://www.eci2, ISSN: , DOI:
Abstracts Book, 5th European Congress of Immunology, 2-5 September Amsterdam Annual 2020-02-27

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TRANSBIO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TRANSBIO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More